Presagen divests IVF AI line to Japanese manufacturer
Adelaide-based Presagen has sold its line of AI solutions for in vitro fertilisation to Japanese assisted reproductive technology manufacturer, Astec.
The Life Whisperer series assesses embryo and oocyte images. It features AI algorithms that determine an embryo’s likelihood of leading to pregnancy and being genetically normal, evaluate its morphological quality, as well as predict if oocytes can form a good-quality embryo or blastocyst.
“We believe AI will be a core feature of every IVF lab in the future and we are delighted to offer our customers one of the most advanced and validated products in the market,” Astec deputy CEO Takeo Cho said about their acquisition of Life Whisperer, which it has already made available in Japan and Indonesia.
Following this sale, Astec will proceed with a global rollout of the IVF AI solutions.
Sorsix absorbs New Zealand partner
Australian health IT company Sorsix has acquired Aceso Health, one of its partners in New Zealand.
Aceso has been the main carrier of Sorsix’s digital health solutions, including the comprehensive cloud-based hospital system platform Pinga, in New Zealand since 2018.
This acquisition, according to Aceso, will allow Sorsix to focus on its work and engagements in New Zealand by taking over its related party contracts and business.
Orion Health announces integration with Te Whatu Ora’s Streamliners
Orion Health has partnered with Streamliners, a company jointly owned by The Joined Up Systems Trust and Te Whatu Ora, for technology integration.
They will offer a combined solution by integrating Orion’s Amadeus digital care records and Streamliners’ HealthPathways, an online clinicians’ manual that provides access to the latest global evidence and best practice guidelines on various health conditions.
Based on a media release, the integrated offering will “enhance care coordination, clinical decision-making, and population health management across multiple care settings.”
Integral Diagnostics trials new chest CT AI
ASX-listed medical imaging service provider Integral Diagnostics is trialling new chest CT-based AI algorithms ahead of its participation in the Australian government’s National Lung Cancer Screening Programme (NLCSP) next year.
According to a media release, it has extended its existing partnership deal with Israeli company Aidoc, which provides the aIOS platform that it has been using to flag critical chest and brain pathologies since 2019.
The new AI on aIOS reportedly measures and alerts radiologists of lung nodules in chest CT scans.
The NLCSP will begin screening people at high risk of lung cancer in July next year.
